Repaglinide ( DrugBank: Repaglinide )

3 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
21	Mitochondrial disease	1
299	Cystic fibrosis	4

6. Parkinson disease

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01536366 (ClinicalTrials.gov)	June 2009	23/1/2012	Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide	Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy Volunteers	Parkinson Disease	Drug: BIA 9-1067;Drug: Repaglinide	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	27	Phase 1	Portugal

21. Mitochondrial disease

Clinical trials : 33 / Drugs : 42 - (DrugBank : 32) / Drug target genes : 47 - Drug target pathways : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04643249 (ClinicalTrials.gov)	November 10, 2020	13/11/2020	Drug-drug Interaction Study of KL1333 in Healthy Subjects	A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects	Mitochondrial Disease	Drug: KL1333;Drug: Flurbiprofen;Drug: Dextromethorphan;Drug: Bupropion;Drug: Midazolam injection;Drug: Omeprazole;Drug: Caffeine;Drug: Repaglinide	Abliva AB	NULL	Completed	18 Years	65 Years	All	14	Phase 1	United Kingdom

299. Cystic fibrosis

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00763412 (ClinicalTrials.gov)	November 2006	29/9/2008	Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis	Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis	Cystic Fibrosis Related Diabetes;Pancreatic Insufficiency	Drug: placebo;Drug: repaglinide	Arbelaez, Ana Maria	Washington University School of Medicine;National Institutes of Health (NIH);Novo Nordisk A/S;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	12 Years	24 Years	All	31	N/A	United States
2	NCT00231192 (ClinicalTrials.gov)	October 2005	3/10/2005	Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes	Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes	Diabetes	Drug: Repaglinide and Insulin	Children's Hospital of Philadelphia	NULL	Withdrawn	12 Years	20 Years	Both	0	N/A	United States
3	NCT00662714 (ClinicalTrials.gov)	September 2001	17/4/2008	Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis	Open Randomised Prospective Comparative Multi-centre Intervention Study of Patients With Cystic Fibrosis and Early Diagnosed Diabetes Mellitus	Cystic Fibrosis;Diabetes Mellitus	Drug: Repaglinide;Drug: short-acting Insulin (Actrapid)	Mukoviszidose Institut gGmbH	Novo Nordisk A/S;Mucoviscidose-ABCF2;Assistance Publique - Hôpitaux de Paris	Completed	10 Years	N/A	Both	73	Phase 3	Austria;France;Germany;Italy
4	NCT00072904 (ClinicalTrials.gov)	June 2001	12/11/2003	Diabetes Therapy to Improve BMI and Lung Function in CF	Diabetes Therapy to Improve BMI and Lung Function in CF	Cystic Fibrosis;Diabetes Mellitus	Drug: Insulin Asparte;Drug: Repaglinide	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Cystic Fibrosis Foundation Therapeutics;Novo Nordisk A/S	Completed	16 Years	N/A	Both	108	Phase 3	United States;Canada